CTXRHealthcare · BiotechnologyCTXR Stock Forecast: Citius Pharmaceuticals, Inc. Price Predictions for 2026-2027
The 1 Wall Street analysts covering Citius Pharmaceuticals, Inc. hold a median 12-month price target of $4 — +571.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
CTXR stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Citius Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (90): Smaller than most of the companies we track.
Momentum (12): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own Citius Pharmaceuticals, Inc. — and when they’d sell — is the membership.
CTXR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CTXR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +571.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 May 2026 | HC Wainwright & Co. | Assumes | Buy | $4.00 |
| 11 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 4 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 13 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 30 June 2025 | D. Boral Capital | Maintains | Buy | — |
| 10 June 2025 | D. Boral Capital | Maintains | Buy | — |
| 9 June 2025 | D. Boral Capital | Maintains | Buy | — |
| 23 May 2025 | Maxim Group | Downgrade | Hold | — |
| 15 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 18 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 7 Jan 2025 | D. Boral Capital | Maintains | Buy | — |
| 30 Dec 2024 | D. Boral Capital | Upgrade | Buy | — |
| 22 Nov 2024 | D. Boral Capital | Downgrade | Hold | — |
| 12 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Nov 2024 | D. Boral Capital | Maintains | Buy | — |
| 19 Aug 2024 | EF Hutton | Maintains | Buy | — |
| 8 Aug 2024 | EF Hutton | Maintains | Buy | — |
| 5 Aug 2024 | EF Hutton | Maintains | Buy | — |
| 15 July 2024 | EF Hutton | Initiates | Buy | — |
| 31 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CTXR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Citius Pharmaceuticals, Inc. (CTXR) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.2×
- Price / sales
- 2.8×
- Price / book
- 0.2×
- EV / EBITDA
- −0.4×
Cheaper than 77% of US stocks
Cheaper than 44% of US stocks
Cheaper than 89% of US stocks
Cheaper than 64% of US stocks
- Revenue growth (YoY)
- −57.7%
- Earnings growth (YoY)
- —
- Gross margin
- 80.3%
- Operating margin
- −1827.8%
- Net margin
- 0.0%
Higher than 4% of US stocks
Higher than 91% of US stocks
Higher than 5% of US stocks
Higher than 30% of US stocks
- Return on equity
- −83.6%
- Return on assets
- −27.6%
- Dividend yield
- —
Higher than 15% of US stocks
Higher than 15% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
CTXR vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CTXR appears on the weeks it earns a place.
Frequently asked questions about CTXR stock
What is the CTXR stock price forecast for 2026-2027?
The 1 Wall Street analysts covering Citius Pharmaceuticals, Inc. have a median 12-month price target of $4, with estimates ranging from $4 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is CTXR stock a buy right now?
Of the 1 analysts covering Citius Pharmaceuticals, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Citius Pharmaceuticals, Inc. 27 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CTXR?
As at 1 Aug 2026, Citius Pharmaceuticals, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).
Will CTXR stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +571.1% from the last close, and Ticker Nerd's factor model ranks Citius Pharmaceuticals, Inc. 27 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the CTXR stock forecast for 2030?
No analyst covering Citius Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTXR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.
How has CTXR stock performed over the past year?
Citius Pharmaceuticals, Inc. returned -53.8% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Citius Pharmaceuticals, Inc. do?
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company specializing in the development and commercialization of first-in-class critical care products.
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company specializing in the development and commercialization of first-in-class critical care products. The company focuses on innovative therapies primarily in anti-infectives, oncology, adjunct cancer care, stem cell therapy, and unique prescription products. Its diverse pipeline includes candidates targeting serious medical conditions, reflecting a commitment to advancing treatments that address critical unmet needs in healthcare. With a strategic emphasis on critical care and oncology-related therapeutics, Citius plays a significant role in the pharmaceutical industry by aiming to improve patient outcomes through novel drug development. Headquartered in Cranford, New Jersey, Citius Pharmaceuticals leverages its clinical expertise to progress products through late-stage development toward commercialization.
CEO Mr. Leonard L. Mazur · 23 employees · United States · https://citiuspharma.com